【佳学基因检测】补充硒对不孕多囊卵巢综合征女性体外受精候选者胰岛素和脂质相关基因表达的影响：一项随机、双盲、安慰剂对照试验

中国肿瘤基因检测公司排名详解

讨化肿瘤个性化药物研究路径做了备注《Biol Trace Elem Res》在. 2018 Jun;183(2):218-225.发表了一篇题目为《补充硒对不孕多囊卵巢综合征女性体外受精候选者胰岛素和脂质相关基因表达的影响：一项随机、双盲、安慰剂对照试验》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Shahrzad Zadeh Modarres , Zahra Heidar , Fatemeh Foroozanfard , Zahra Rahmati , Esmat Aghadavod , Zatollah Asemi 等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤的遗传阻断临床研究内容关键词：

体外受精,IVF,候选,多囊卵巢综合征,PCOS,不孕女性,胰岛素,脂质,基因表达

肿瘤靶向治疗基因检测临床应用结果

本研究旨在评估硒补充剂对体外受精 (IVF) 候选多囊卵巢综合征 (PCOS) 不孕女性胰岛素和脂质相关基因表达的影响。这项随机双盲、安慰剂对照试验是在 40 名患有 PCOS 的不孕女性中进行的。受试者被随机分为两组，每天摄入 200 μg 硒（n = 20）或安慰剂（n = 20），持续 8 周。用 RT-PCR 方法在患有 PCOS 候选 IVF 的女性的淋巴细胞中量化与胰岛素和脂质相关的基因表达水平。 RT-PCR 的结果表明，在 8 周的干预后，与安慰剂相比，硒补充剂上调了过氧化物酶体增殖物激活受体 γ (PPAR-γ) 的基因表达（增加了 1.06 ± 0.15 倍对 0.94 ± 0.18 倍）减少，P = 0.02）和葡萄糖转运蛋白 1（GLUT-1）（增加 1.07 ± 0.20 倍与减少 0.87 ± 0.18 倍，P = 0.003）在 PCOS 候选 IVF 女性的淋巴细胞中。此外，与安慰剂相比，补充硒可下调 PCOS 候选患者淋巴细胞中低密度脂蛋白受体 (LDLR) 的基因表达（减少 0.88 ± 0.17 倍 vs. 增加 1.05 ± 0.22 倍，P = 0.01）。体外受精。我们没有观察到补充硒对 IVF 候选 PCOS 女性淋巴细胞中脂蛋白 (a) [LP(a)] 基因表达水平的任何显着影响。总体而言，在体外受精的不孕 PCOS 候选者的淋巴细胞中补充硒 8 周显着增加了 PPAR-γ 和 GLUT-1 的基因表达水平，并显着降低了 LDLR 的基因表达水平，但不影响 LP(a)。临床试验注册号：http://www.irct.ir：IRCT201704245623N113.Keywords：基因表达；胰岛素;脂质；多囊卵巢综合征;补硒。

肿瘤发生与复发转移国际数据库描述：

This study was conducted to evaluate the effects of selenium supplementation on gene expression related to insulin and lipid in infertile women with polycystic ovary syndrome (PCOS) candidate for in vitro fertilization (IVF). This randomized double-blind, placebo-controlled trial was conducted among 40 infertile women with PCOS candidate for IVF. Subjects were randomly allocated into two groups to intake either 200-μg selenium (n = 20) or placebo (n = 20) per day for 8 weeks. Gene expression levels related to insulin and lipid were quantified in lymphocytes of women with PCOS candidate for IVF with RT-PCR method. Results of RT-PCR demonstrated that after the 8-week intervention, compared with the placebo, selenium supplementation upregulated gene expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) (1.06 ± 0.15-fold increase vs. 0.94 ± 0.18-fold reduction, P = 0.02) and glucose transporter 1 (GLUT-1) (1.07 ± 0.20-fold increase vs. 0.87 ± 0.18-fold reduction, P = 0.003) in lymphocytes of women with PCOS candidate for IVF. In addition, compared with the placebo, selenium supplementation downregulated gene expression of low-density lipoprotein receptor (LDLR) (0.88 ± 0.17-fold reduction vs. 1.05 ± 0.22-fold increase, P = 0.01) in lymphocytes of women with PCOS candidate for IVF. We did not observe any significant effect of selenium supplementation on gene expression levels of lipoprotein(a) [LP(a)] in lymphocytes of women with PCOS candidate for IVF. Overall, selenium supplementation for 8 weeks in lymphocytes of women with infertile PCOS candidate for IVF significantly increased gene expression levels of PPAR-γ and GLUT-1 and significantly decreased gene expression levels of LDLR, but did not affect LP(a).Clinical trial registration number: http://www.irct.ir : IRCT201704245623N113.Keywords: Gene expression; Insulin; Lipid; Polycystic ovary syndrome; Selenium supplementation.